Product name
Second Indications for Proteasome InhibitorsSummary
Proteasome inhibitors for the treatment of HCMV, myocardial fibrosis and cardiac hypertrophyOrganization name
IPAL GmbHProfile
Proteasome inhibitors represent a class of drugs that may prove effective in fi ghting a wide range of diseases especially cancers. Apart from classical indications several new indications for therapies with proteasome inhibitors arise. We offer second medical application for treatment of human cytomegalovirus (HCMV), myofi brosis and cardiovascular diseases.
Herpes viridae Infections
In contrast to current antiviral agents which act as inhibitors of the HCMV DNA-polymerase, the new Charité compounds are able to block immediate early and early gene expression of the virus before initiation of viral DNA replication occurs. Syntheses of viral late proteins, representing viral structure proteins are also signifi cantly reduced as confi rmed by in vivo experiments.
Fibrotic Diseases
It was demonstrated that proteasome inhibitors can be used for the treatment of fibrotic diseases especially fibrotic diseases of the cardiovascular system (like myocardial fibrosis) that are not induced by an inflammation. In a spontaneous hypertensive rat animal model, the tested proteasome inhibitors reduced cardiac fibrosis up to 40%.
It was shown in vitro that a concentration- dependent inhibition of the growth of cardiac fibroblasts and a down-regulation of collagen Iα2 by approximately 75% and of collagen IIIα1 by approximately 90%. Although one would have expected systemic cytotoxicity, the described long-term treatment did not result in measurable side effects, but in contrast was well tolerated.
Cardiovascular Diseases
Inhibition of the ubiquitin-proteasome pathway in neonatal rat cardiomyocytes was shown to oppose and avert the formation of cardiac hypertrophy. The regulation acts via the enzyme endothelial nitric oxide synthase which produces nitric oxide, a key molecule in vasodilatation and atheroprotection.
The inventors show that proteasome inhibitors enhance the availability of nitric oxide in endothelial cells and increase endothelium-dependent vasodilatation in vivo.
International patents have been filed. Additional information is provided in the attached pdf.
The inhibitors are offered by IPAL.
Contact
IPAL GmbH
Dr. Christian Wunsch
christian.wunsch(at)ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
Description File
02087_ProteasomenIndikation.pdf
print this page
